Regeneron Pharmaceuticals Analyst Price Targets

PRO

Pourquoi cela bouge-t-il ?:Regeneron Pharmaceuticals shares are trading higher after multiple analyst ...

Résultats: Les résultats Q3 2026 ont été publiés le ven. oct. 30th, avant l'ouverture du marché

Conférence téléphonique: La conférence téléphonique la plus récente a commencé à 8:30 AM, il y a 4 jours

Cliquez pour voir la webdiffusion

Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 6 Quarters

Analyst Consensus — 23 Analysts

17Buy

6Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$887Upside to Avg. PT-8.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Leerink Partners	David Risinger	PT Raise	Market Perform	$835→$997
Nov 2, 2026	Bernstein	Jeffrey Walch	PT Raise	Market Perform	$756→$812
Nov 2, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$779→$855
Nov 2, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$810→$913
Nov 2, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$780→$982
Nov 2, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$1030→$1100
Nov 2, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$750→$925
Nov 2, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$900→$1075
Nov 2, 2026	Canaccord Genuity	John Newman	PT Raise	Buy	$922→$1175
Nov 2, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$795→$980
Nov 2, 2026	Baird	Brian Skorney	PT Raise	Neutral	$761→$875
Nov 2, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$908→$1030
Oct 30, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$950→$1050
Oct 30, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$740→$825
Oct 28, 2026	Canaccord Genuity	John Newman	PT Raise	Buy	$875→$922
Oct 21, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$960→$980
Oct 19, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$854→$865
Oct 15, 2026	UBS	Trung Huynh	Upgrade	Neutral→Buy	$660→$978
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$737→$810
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$772→$780

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.

Benzinga Newsdesk

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

Bernstein analyst Jeffrey Walch maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $756 to $812.

Benzinga Newsdesk

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $779 to $855.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $810 to $913.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $780 to $982.

Benzinga Newsdesk

Regeneron Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

People Also Watch

People Also Watch

Regeneron Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PROBernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PROCNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PROMorgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRORBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PROTruist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982